Forxiga recommended for approval in the EU by CHMP for symptomatic chronic heart failure
If approved, Forxiga will be the first heart failure therapy indicated across the full ejection fraction range with proven mortality reduction.AstraZeneca’s Forxiga (dapagliflozin) has been recommended for approval in the European Union (EU) to extend the indication for heart failure with reduced ejection fraction (HFrEF) to cover patients across the full spectrum of left ventricular ejection fraction (LVEF) including HF with mildly reduced and preserved ejection fraction (HFmrEF, HFpEF). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its